{"protocolSection":{"identificationModule":{"nctId":"NCT06625398","orgStudyIdInfo":{"id":"VRDN-003-302"},"organization":{"fullName":"Viridian Therapeutics, Inc.","class":"INDUSTRY"},"briefTitle":"An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)","officialTitle":"REVEAL-2 - A Phase 3, Randomized, Double-masked, Placebo-controlled, Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)","acronym":"REVEAL-2"},"statusModule":{"statusVerifiedDate":"2025-09","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-08-27","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-04-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-12-15","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-10-01","studyFirstSubmitQcDate":"2024-10-02","studyFirstPostDateStruct":{"date":"2024-10-03","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-09-24","lastUpdatePostDateStruct":{"date":"2025-09-30","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Viridian Therapeutics, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with chronic Thyroid Eye Disease (TED).","detailedDescription":"This is a randomized (meaning participants will be assigned to study arms by chance), double-masked (meaning study doctor and participant will not know which study arm participant is assigned to), placebo-controlled study that will include participants with chronic TED. The key objectives of this study are to determine if VRDN-003 is efficacious, safe and tolerable when administered as subcutaneous/SC injections every 4 weeks or every 8 weeks compared to placebo in participants with chronic TED.\n\nParticipants who do not have a meaningful response at Week 24 (irrespective of the initial treatment arm) may be eligible to receive additional subcutaneous injections of VRDN-003."},"conditionsModule":{"conditions":["Thyroid Eye Disease"],"keywords":["TED","Thyroid Eye Disease","Graves","Thyroid-Associated Ophthalmopathy","Dysthyroid Ophthalmopathy","Graves Eye Disease","Graves Orbitopathy","Myopathic Ophthalmopathy","Edematous Ophthalmopathy","Infiltrative Ophthalmopathy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"Participants will be randomized to one of the three study arms.","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"TRIPLE","maskingDescription":"Participants will be randomized to one of the three study arms.","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":195,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"VRDN-003 every 4 weeks","type":"EXPERIMENTAL","description":"6 subcutaneous administrations of VRDN-003","interventionNames":["Drug: VRDN-003"]},{"label":"VRDN-003 every 8 weeks","type":"EXPERIMENTAL","description":"3 subcutaneous administrations of VRDN-003 and 3 subcutaneous administrations of placebo","interventionNames":["Drug: VRDN-003","Drug: Placebo"]},{"label":"Placebo every 4 weeks","type":"PLACEBO_COMPARATOR","description":"6 subcutaneous administrations of placebo","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"VRDN-003","description":"VRDN-003 is an investigational, subcutaneously administered, humanized monoclonal antibody directed against the Insulin-like Growth Factor-1 receptor (IGF-1R).","armGroupLabels":["VRDN-003 every 4 weeks","VRDN-003 every 8 weeks"]},{"type":"DRUG","name":"Placebo","description":"All participants will receive the same number of injections to maintain masking. Masking will be maintained by the use of placebo injections that appear identical to VRDN-003 injections.","armGroupLabels":["Placebo every 4 weeks","VRDN-003 every 8 weeks"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Title: Proptosis Responder Rate in the study eye","description":"Description: Proportion of participants with a ≥2 mm reduction from baseline in proptosis in the study eye \\[without a corresponding increase of ≥2 mm in the fellow eye\\]","timeFrame":"At Week 24"}],"secondaryOutcomes":[{"measure":"Change from baseline in proptosis in the study eye","description":"Change from baseline in proptosis in the study eye","timeFrame":"At Week 24"},{"measure":"Overall Responder Rate in the study eye","description":"Proportion of participants with a ≥2 mm reduction from baseline in proptosis in the study eye \\[without a corresponding increase of ≥2 mm in the fellow eye\\] AND no worsening in CAS from baseline in the study eye \\[without a corresponding increase of ≥2 points in the fellow eye\\]","timeFrame":"At Week 24"},{"measure":"Diplopia Responder Rate for participants with baseline Diplopia Score greater than 0","description":"Proportion of participants with a reduction in Diplopia Score of ≥1 from baseline (for participants with baseline Diplopia Score greater than 0)","timeFrame":"At Week 24"},{"measure":"Diplopia Resolution Rate for participants with baseline Diplopia Score greater than 0","description":"Proportion of participants with a reduction in Diplopia Score to 0 from baseline (for participants with baseline Diplopia Score greater than 0)","timeFrame":"At Week 24"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Must have moderate to severe chronic TED, with any CAS (0-7) on the 7-item scale, and with documented evidence of ocular symptoms or signs that began greater than 15 months prior to screening\n* Must agree to use highly effective contraception as specified in the protocol\n* Female TED participants must have a negative serum pregnancy test at screening\n\nKey Exclusion Criteria:\n\n* Must not have received prior treatment with another anti-IGF-1R therapy\n* Must not have received systemic corticosteroids or steroid eye drops for any condition, including TED, or selenium within 2 weeks prior to first dose.\n* Must not have received other immunosuppressive drugs for any condition, including TED, or any other therapy for TED within 12 weeks prior to first dose\n* Must not have received an investigational agent for any condition, including TED, within 8 weeks or longer duration (depending on the type of investigational agent) prior to first dose\n* Must not have received radioactive iodine (RAI) treatment within 8 weeks prior to first dose\n* Must not have had previous orbital irradiation or decompression surgery for TED to the study eye's orbit\n* Must not have a pre-existing ophthalmic condition in the study eye which in the study doctor's opinion, would interfere with interpretation of study results\n* Must not have abnormal hearing test before first dose. Must also not have a history of ear conditions considered significant by study doctor\n* Must not have a history of inflammatory bowel disease\n* Female TED participants must not be pregnant or breastfeeding\n\nNOTE: There are additional eligibility criteria for participants who do not have a meaningful response at Week 24 (irrespective of initial treatment arm) who may receive additional injections of VRDN-003. These are described in the protocol.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Scottsdale Clinical Trials","city":"Scottsdale","state":"Arizona","zip":"85260","country":"United States","geoPoint":{"lat":33.50921,"lon":-111.89903}},{"facility":"Alliance Research Institute - Canoga Park","city":"Canoga Park","state":"California","zip":"91304","country":"United States","geoPoint":{"lat":34.20112,"lon":-118.59814}},{"facility":"Marvel Clinical Research","city":"Huntington Beach","state":"California","zip":"92647","country":"United States","geoPoint":{"lat":33.6603,"lon":-117.99923}},{"facility":"United Medical Research Institute","city":"Inglewood","state":"California","zip":"90301","country":"United States","geoPoint":{"lat":33.96168,"lon":-118.35313}},{"facility":"Advancing Research International, LLC","city":"Los Angeles","state":"California","zip":"90023","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Roski Eye Institute, Keck School of Medicine, USC","city":"Los Angeles","state":"California","zip":"90033","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Alliance Research Institute - Lynwood","city":"Lynwood","state":"California","zip":"90262","country":"United States","geoPoint":{"lat":33.93029,"lon":-118.21146}},{"facility":"A.P.J. Office","city":"Newport Beach","state":"California","zip":"92660","country":"United States","geoPoint":{"lat":33.61891,"lon":-117.92895}},{"facility":"Byers Eye Institute at Stanford University","city":"Palo Alto","state":"California","zip":"94303","country":"United States","geoPoint":{"lat":37.44188,"lon":-122.14302}},{"facility":"Pasadena Clinical Trials","city":"Pasadena","state":"California","zip":"91101","country":"United States","geoPoint":{"lat":34.14778,"lon":-118.14452}},{"facility":"Senta Clinic","city":"San Diego","state":"California","zip":"92108","country":"United States","geoPoint":{"lat":32.71571,"lon":-117.16472}},{"facility":"Ilumina Medical Research","city":"Kissimmee","state":"Florida","zip":"34744","country":"United States","geoPoint":{"lat":28.30468,"lon":-81.41667}},{"facility":"Med-Care Research","city":"Miami","state":"Florida","zip":"33125","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Hype Clinical Research LLC","city":"Miami","state":"Florida","zip":"33145","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Anmed Health Services LLC","city":"Miami","state":"Florida","zip":"33193","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Southern Clinical Research LLc","city":"Miami","state":"Florida","zip":"33990","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Sarasota Retina Institute","city":"Sarasota","state":"Florida","zip":"34239","country":"United States","geoPoint":{"lat":27.33643,"lon":-82.53065}},{"facility":"Agile Clinical Research Trials, LLC","city":"Atlanta","state":"Georgia","zip":"30328","country":"United States","geoPoint":{"lat":33.749,"lon":-84.38798}},{"facility":"Vision Medical Research","city":"Orland Park","state":"Illinois","zip":"60462","country":"United States","geoPoint":{"lat":41.63031,"lon":-87.85394}},{"facility":"Massachusetts Eye and Ear","city":"Boston","state":"Massachusetts","zip":"02114","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Opthalmic Consultants of Boston","city":"East Weymouth","state":"Massachusetts","zip":"02189","country":"United States","geoPoint":{"lat":42.21399,"lon":-70.92032}},{"facility":"Fraser Eye Care Center","city":"Fraser","state":"Michigan","zip":"48026","country":"United States","geoPoint":{"lat":42.5392,"lon":-82.94937}},{"facility":"Kahana Oculoplastic & Orbital Surgery","city":"Livonia","state":"Michigan","zip":"48152","country":"United States","geoPoint":{"lat":42.36837,"lon":-83.35271}},{"facility":"University Health","city":"Kansas City","state":"Missouri","zip":"64108","country":"United States","geoPoint":{"lat":39.09973,"lon":-94.57857}},{"facility":"S.L. Office","city":"Las Vegas","state":"Nevada","zip":"89144","country":"United States","geoPoint":{"lat":36.17497,"lon":-115.13722}},{"facility":"Vector Clinical Trials","city":"Sparks","state":"Nevada","zip":"89436","country":"United States","geoPoint":{"lat":39.53491,"lon":-119.75269}},{"facility":"Rutgers New Jersey Medical School","city":"Newark","state":"New Jersey","zip":"07103","country":"United States","geoPoint":{"lat":40.73566,"lon":-74.17237}},{"facility":"Asheville Clinical Research","city":"Asheville","state":"North Carolina","zip":"28803","country":"United States","geoPoint":{"lat":35.60095,"lon":-82.55402}},{"facility":"Duke Eye Center","city":"Durham","state":"North Carolina","zip":"27710","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"Scheie Eye Institute Penn Presbyterian","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Wills Eye Hospital","city":"Philadelphia","state":"Pennsylvania","zip":"19107","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"Horizon Clinical Research Group","city":"Cypress","state":"Texas","zip":"77429","country":"United States","geoPoint":{"lat":29.96911,"lon":-95.69717}},{"facility":"Baylor College of Medicine/Alkek Eye Center","city":"Houston","state":"Texas","zip":"77030","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Gulf Coast Clinical Trials","city":"Houston","state":"Texas","zip":"77070","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"Neuro-Eye Clinical Trials","city":"Houston","state":"Texas","zip":"77074","country":"United States","geoPoint":{"lat":29.76328,"lon":-95.36327}},{"facility":"University of Washington, Eye institute","city":"Seattle","state":"Washington","zip":"98104","country":"United States","geoPoint":{"lat":47.60621,"lon":-122.33207}},{"facility":"West Virginia University Eye Institute","city":"Morgantown","state":"West Virginia","zip":"26506","country":"United States","geoPoint":{"lat":39.62953,"lon":-79.9559}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D049970","term":"Graves Ophthalmopathy"}],"ancestors":[{"id":"D015785","term":"Eye Diseases, Hereditary"},{"id":"D005128","term":"Eye Diseases"},{"id":"D006111","term":"Graves Disease"},{"id":"D005094","term":"Exophthalmos"},{"id":"D009916","term":"Orbital Diseases"},{"id":"D030342","term":"Genetic Diseases, Inborn"},{"id":"D009358","term":"Congenital, Hereditary, and Neonatal Diseases and Abnormalities"},{"id":"D006042","term":"Goiter"},{"id":"D013959","term":"Thyroid Diseases"},{"id":"D004700","term":"Endocrine System Diseases"},{"id":"D006980","term":"Hyperthyroidism"},{"id":"D001327","term":"Autoimmune Diseases"},{"id":"D007154","term":"Immune System Diseases"}]}},"hasResults":false}